All In Biotech

NDA 021821 · Pf Prism Cv

Tygacil

Tigecycline · Intravenous · Tetracycline-class Antibacterial

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jun 15, 2005

Approved uses

4

Original approval plus efficacy supplements

Registered trials

64

23 Phase 3, 6 recruiting

FAERS reports

6,220

5,767 serious, 1,654 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ALL-CAUSE MORTALITY An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in TYGACIL-treated patients versus comparator. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. TYGACIL should be reserved for use in situations when alternative treatments are not suitable [see Indications and Usage (1.4) , Warnings and Precautions (5.1 , 5.2) and Adverse Reactions (6.1) ]. WARNING: ALL-CAUSE MORTALITY See full prescribing information for complete boxed warning. All-cause mortality was higher in patients treated with TYGACIL than comparators in a meta-analysis of clinical trials. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. TYGACIL should be reserved for use in situations when alternative treatments are not suitable ( 1.4 , 5.1 , 5.2 , 6.1 ).

What it is approved for

From the label in effect Nov 18, 2025.

TYGACIL is a tetracycline class antibacterial indicated in patients 18 years of age and older for: • Complicated skin and skin structure infections ( 1.1 ) • Complicated intra-abdominal infections ( 1.2 ) • Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : TYGACIL is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia ( 1.4 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.5 ). 1.1 Complicated Skin and Skin Structure Infections TYGACIL is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus ), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis. 1.2 Complicated Intra-abdominal Infections TYGACIL is indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections caused by susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus ), Bacteroides fragilis, Bacteroides...

Mechanism: Tigecycline is a tetracycline class antibacterial [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TYGACIL · TIGECYCLINE 50MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Tigecycline" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective763
  • off label use696
  • nausea417
  • vomiting283
  • sepsis270
  • thrombocytopenia261
  • death258
  • septic shock243
  • drug resistance225
  • coagulopathy216
  • diarrhoea213
  • condition aggravated205

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200520
200676
2007139
2008152
2009175
2010205
2011183
2012159
2013181
2014136
2015215
2016178
2017305
2018329
2019525
2020445
2021473
2022402
2023505
2024598
2025486
2026333

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tygacil (Tigecycline)

2024 spending

$243K

Beneficiaries

61

215 claims

Per beneficiary

$3,985

$8.78 per unit

View as table
YearSpending
2020$712,996
2021$500,787
2022$352,330
2023$269,271
2024$243,073

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 191 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.